INDEX

VOLUME 22 — 1967

A

Aarons, Morris.—Factory Inspection. July, p. 407.

Additives

Food Additives in Japan. Nov., p. 611.

Administrative Inspection of Health Facilities as Unreasonable Searches. Aug., p. 456.

Administrator's View (The). Aug., p. 449.

Advertising

Advertising of Health Literature to the General Public. Jan., p. 4.

FDA Goals in Labeling and Advertising Regulations. May, p. 300.

Food and Drug Advertising and Pricing Problems Under the Combines Investigation Act. Apr., p. 222.

Forward With A Backword Look. July, p. 395.

Safe and Effective Prescription-Drug Advertising. Jan., p. 57.

The Administrator's View. Aug., p. 449.

What FDA Expects in Prescription Drug Advertising. Jan., p. 46.

Advertising of Health Literature to the General Public. Jan., p. 4.

Akau, George H.—New Developments in Food and Drug Legislation in Hawaii. Sept., p. 478.

An Ombudsman for Industry. Sept., p. 472.

Antibiotic Residues in Food. Jan., p. 41.

Antibiotics

Antibiotic Residues in Food. Jan., p. 41.

Veterinary Medical and Nonmedical Uses of Antibiotics. Jan., p. 33.

Antitrust Aspects of Industry Cooperation and Product Standardization. June, p. 361.

Assuring Drug Integrity—New Challenges, New Horizons. Feb., p. 85.

Assuring Integrity Through Teamwork. Jan., p. 54.

Austern, H. Thomas.—Is Government by Exhortation Desirable? Dec., p. 647.

B

Baby Foods

Does the Term "Special Dietary Use" Apply to All Baby Foods? Sept., p. 518.

Barnard, Alfred.—Good Manufacturing Practices Regulations in the Food Industry. Sept., p. 511.

Bledel, Enrique E.—The Latin-American Common Market and Food Legislation. July, p. 402.

Buday, Paul V.—The Package Insert: Significance, Style, Synthesis. Oct., p. 547.

Burditt, George M.

Fair Packaging and Labeling—The Cost to Consumers. Oct., p. 542.

Good Manufacturing Practice Regulations for the Food Industry. Dec., p. 677.

Proposed Amendments to the Model Food and Drug Law. May, p. 304.

C

Canada

Food and Drug Advertising and Pricing Problems Under the Combines Investigation Act. Apr., p. 222.

The Canadian Viewpoint. Mar., p. 185.

Industry Problems in the Drug Field in Canada. Apr., p. 211.

Trends in Drug Legislation Under the Food and Drugs Act in Canada. Mar., p. 189.

Canadian Viewpoint (The). Mar., p. 185.

Chapman, R. A.—The Canadian Viewpoint. Mar., p. 185.
Color Additive Amendments of 1960
The Color Additive Amendments of 1960 Revisited. Oct., p. 553.
Color Additive Amendments of 1960 Revisited—Seven Years of Feast or Famine (The). Oct., p. 553.
Combines Investigation Act
Food and Drug Advertising and Pricing Problems Under the Combines Investigation Act. Apr., p. 222.
Communicating in the Public Interest. Dec., p. 632.
Condon, William J.—Product Liability—1966. Feb., p. 125.
Consumer Protection
Communicating in the Public Interest. Dec., p. 632.
Government and Consumer Protection—Drugs. Nov., p. 593.
In the Public Interest. Dec., p. 638.
President's message. Feb., p. 132.
Report From FDA. Feb., p. 68.
The Administrator's View. Aug., p. 449.
The Year in Review. Feb., p. 92.
Cooperation
FDA — Management Cooperation. Nov., p. 589.
Coordination of Federal-State Responsibilities: The State Perspective. June, p. 368.
"Cosmetic" or "Drug"—The Minotaur's Labyrinth. July, p. 376.
Cosmetics
"Cosmetic" or "Drug"—The Minotaur's Labyrinth. July, p. 376.
Costello, Joseph M. — Multiple Drug Litigation—The Defendant's Viewpoint. Mar., p. 145.
Coston, Dean W.—The Role of the Department of Health, Education and Welfare. June, p. 334.
Curran, R. E., Q. C.—Trends in Drug Legislation Under the Food and Drugs Act in Canada. Mar., p. 189.

D

Daubert, B. F.—Voluntary Compliance. Dec., p. 672.
Delmore, Fred J.—Welcoming Remarks (1966 FDA-FDLI Conference). Jan., p. 18.
Department of Commerce
The Role of the Department of Commerce. June, p. 327.
Department of Health, Education and Welfare
The Role of the Department of Health Education and Welfare. June, p. 334.
Depew, Franklin M.
Does the Term "Special Dietary Use" Apply to All Baby Foods? Sept., p. 518.
Introductory Statement (1967 Meeting of the Section on Food, Drug and Cosmetic Law of the New York State Bar Association). Feb., p. 91.
Review of *Fundamental Principles and Objectives of a Comparative Food Law: Volume* 1, by E. J. Bigwood and A. Gérard. May, p. 307.
Review of *Use of Human Subjects in Safety Evaluation of Food Chemicals: Proceedings of a Conference.* Oct., p. 569.
Dietary Foods
Does the Term "Special Dietary Use" Apply to All Baby Foods? Sept., p. 518.
Historical outline of regulatory aspects. Feb., p. 110.
Discretionary Regulations Under the Fair Packaging and Labeling Act. June, p. 354.
Dixon, Paul Rand
Assuring Integrity Through Teamwork. Jan., p. 54.
Guidance and Enforcement. Mar., p. 177.
Does the Term "Special Dietary Use" Apply to All Baby Foods? Sept., p. 518.
Drug Abuse Control Amendments
Report From FDA. Feb., p. 68.
Drug Amendments of 1962
"GMP" as an answer to Drug Recalls. Feb., p. 79.
Some Observations on the Current Status of Drug Law. Apr., p. 200.
Drug Integrity
New challenges. Feb., p. 85.

Drug Legislation
Trends under the Food and Drugs Act in Canada. Mar., p. 189.

Drugs
"Cosmetic" or "Drug"—The Minotaur's Labyrinth. July, p. 376.

Dunkelberger, Edward.—Industry Views on FDA's Labeling Proposal and State Regulations. Apr., p. 254.

Dunn, Charles Wesley
Wanted—Lawyer-Statesmen. Apr., p. 242.

F

FDA—Management Cooperation. Nov., p. 589.

FDA Goals in Labeling and Advertising Regulations. May, p. 300.

FDA's New Computer. Oct., p. 572.

FDA's Obligations Under the 1966 Public Information Act. Oct., p. 563.

FDA's Organization: The Reasons for Change. Dec., p. 660.

FDA's Voluntary Compliance Program. Dec., p. 682.

Factory Inspection. July, p. 407.

Factory Inspection Authority—The Statutory Viewpoint. Dec., p. 667.

Fair Packaging and Labeling—The Cost to Consumers. Oct., p. 542.

Fair Packaging and Labeling Act of 1966
An introductory appraisal. June, p. 314.
Antitrust Aspect of Industry Cooperation and Product Standardization. June, p. 361.
Coordination of Federal-State Responsibilities: The State Perspective. June, p. 368.
Discretionary regulations. June, p. 354.
Industry Views on FDA's Labeling Proposal and State Regulations. Apr., p. 254.
Key Issues Posed for FTC Staff by the Act—Coverage of the Act. June, p. 344.
Mandatory Regulations: Labeling Requirements and Regulatory Procedures. June, p. 348.
Packaging Responsibilities of the FTC. Mar., p. 165.
The cost to consumers. Oct., p. 542.
The Fair Packaging and Labeling Act of 1966. Mar., p. 169.
The Issues We Face in Carrying Out The Fair Packaging and Labeling Act. Mar., p. 158.
The Philosophy Behind the Fair Packaging and Labeling Act of 1966. June, p. 322.
The Role of the Department of Health, Education and Welfare. June, p. 334.
The Role of the Federal Trade Commission. June, p. 338.
Truth-In-Packaging Revisited. June, p. 317.

Fair Packaging and Labeling Act of 1966 (The). Mar., p. 169.

Fair Packaging and Labeling Act of 1966: An Introductory Appraisal (The). June, p. 314.

Federal Trade Commission
Guidance and Enforcement. Mar., p. 177.
Key issues posed by the Fair Packaging and Labeling Act. June, p. 344.
Packaging responsibilities. Mar., p. 165.
Position on advertising of health literature. Jan., p. 4.
The Role of the Federal Trade Commission. June, p. 338.
Teamwork with FDA. Jan., p. 54.

Food Additives in Japan. Nov., p. 611.

Food and Drug Administration
Communicating in the Public Interest. Dec., p. 632.
Labeling proposal and state regulations. Apr., p. 254.
Observations on Recent Developments in the Food, Drug and Cosmetic Law Field. Mar., p. 151.
Position on advertising of health literature. Jan., p. 4.
Teamwork with FTC. Jan., p. 54.
What FDA Expects in Prescription Drug Advertising. Jan., p. 46.
What the Public Expects of FDA—A Third Party Arbiter. Apr., p. 234.

Food and Drug Advertising and Pricing Problems Under the Combines Investigation Act. Apr., p. 222.

Food and Drug Regulatory Programs in England, Wales and Scotland. Nov., p. 576.

Food Legislation

The Latin-American Common Market and Food Legislation. July, p. 402.

Similarities of and Differences Between the Food Laws of France and the United States. July, p. 386.

Food Standards

International Food Standards: Status Report. Feb., p. 75.

Reflections on Food Standards. Feb., p. 100.

Foods for Special Dietary Uses—An Historical Outline of Regulatory Aspects. Feb., p. 110.

Forward with a Backward Look. July, p. 395.

France

Similarities of and Differences Between the Food Laws of France and the United States. July, p. 386.

Freedman, Warren.—Products Liability Today: Whither Thou Goest, I Will Go (A Modern Tale of Biblical Ruth and Naomi.) Sept., p. 486.

Fundamental Principles and Objectives of a Comparative Food Law: Volume 1 (Review of). May, p. 307.

G

"GMP" as an Answer to Drug Recalls. Feb., p. 79.

Gilbert, A. M.—Observations on Recent Developments in the Food, Drug and Cosmetic Law Field. Mar., p. 151.

Giles, Robert E.—The Fair Packaging and Labeling Act of 1966. Mar., p. 169.

Goddard, James L.

The Year in Review. Feb., p. 92.

Report from FDA. Feb., p. 68.

Pharmacy and the Future. Nov., p. 602

The Administrator's View. Aug., p. 449.

Communicating in the Public Interest. Dec., p. 632.

Goldberg, Herbert S.—Veterinary Medical and Nonmedical Uses of Antibiotics. Jan., p. 33.

Good Manufacturing Practice Regulations

"GMP" as an Answer to Drug Recalls. Feb., p. 79.

Good Manufacturing Practice Regulations for the Food Industry. Dec., p. 677.

Good Manufacturing Practices Regulations in the Food Industry. Sept., p. 511.

Good Manufacturing Practice Regulations for the Food Industry. Dec., p. 677.

Good Manufacturing Practices Regulations in the Food Industry. Sept., p. 511.

Goodrich, William W.

What the Public Expects of FDA—A Third Party Arbiter. Apr., p. 234.

What FDA Expects in Prescription Drug Advertising. Jan., p. 46.

The Issues We Face in Carrying Out The Fair Packaging and Labeling Act. Mar., p. 158.

Rule-Making as Viewed by the Commissioner, the Congress, and the Court. Nov., p. 613.

Discretionary Regulations Under the Fair Packaging and Labeling Act. June, p. 354.

Status of Major Proposals and Regulations. Dec., p. 642.

Government and Consumer Protection—Drugs. Nov., p. 593.

Grange, George R.—International Food Standards: Status Report. Feb., p. 75.

Guaranty Law

A Quick Look at a Bad Decision. Aug., p. 416.

Guidance and Enforcement. Mar., p. 177.

H

Hansen, Douglas C.—"GMP" as an Answer to Drug Recalls. Feb., p. 79.

Hart, Philip A.—Truth-In-Packaging Revisited. June, p. 317.

Hauser, Julius.—FDA Goals in Labeling and Advertising Regulations. May, p. 300.

Hawaii

New Developments in Food and Drug Legislation in Hawaii. Sept., p. 478.

Henry, David H. W.—Food and Drug Advertising and Pricing Problems Under the Combines Investigation Act. Apr., p. 222.

Hoge, James F.—Forward with a Backward Look. July, p. 395.

Hollomon, J. Herbert.—The Role of the Department of Commerce. June, p. 327.

Hume, Frederick R.—Industry Problems in the Drug Field in Canada. Apr., p. 211.

Hutt, Peter Barton.—Factory Inspection Authority—The Statutory Viewpoint. Dec., p. 667.

I

In the Public Interest. Dec., p. 638.

Industry Cooperation and Product Standardization

Antitrust aspects. June, p. 361.

Industry Problems in the Drug Field in Canada. Apr., p. 211.

Industry Views on FDA's Labeling Proposal and State Regulations. Apr., p. 254.

International Food Standards: Status Report. Feb., p. 75.

Introductory Statement (1967 Meeting of the Section of Food, Drug and Cosmetic Law of the New York State Bar Association). Feb., p. 91.

Is Government by Exhortation Desirable? Dec., p. 647.

Issues We Face in Carrying Out The Fair Packaging and Labeling Act (The). Mar., p. 158.

J

Japan

Food Additives in Japan. Nov., p. 611.

Jennings, Matt.—Coordination of Federal-State Responsibilities: The State Perspective. June, p. 368.

Jurow, Irving H.

Safe and Effective Prescription-Drug Advertising. Jan., p. 57.

Government and Consumer Protection—Drugs. Nov., p. 593.

K

Kaplan, Alan H.—The Color Additive Amendments of 1960 Revisited—Seven Years of Feast or Famine. Oct., p. 553.

Kedzior, John A.—FDA's Voluntary Compliance Program. Dec., p. 682.

Key Issues Posed for FTC Staff by the Act—Coverage of the Act. June, p. 344.

Kirk, J. K.—Mandatory Regulations: Labeling Requirements and Regulatory Procedures. June, p. 348.

Kleinfeld, Vincent A.

"Cosmetic" or "Drug"—The Minotaur's Labyrinth. July, p. 376.

An Ombudsman for Industry. Sept., p. 472.

Reflections on Food Standards. Feb., p. 100.

Some Observations on the Current Status of Drug Law. Apr., p. 200.

L

Ladimer, Irving.—Advertising of Health Literature to the General Public. Jan., p. 4.

Lannon, E. R.—FDA's New Computer. Oct., p. 572.

Latin America

The Latin-American Common Market and Food Legislation. July, p. 402.

Latin-American Common Market and Food Legislation (The). July, p. 402.

Latin-American Food Code

Chapter VI. Aug., p. 421.

Chapter XV. Oct., p. 528.

Chapter XVI. May, p. 285.

Lennington, Kenneth R.

Salmonella—History and Occurrence in Foods. Jan., p. 20.

Status and Review of the Salmonella Program. Dec., p. 655.

M

Mamana, Joseph M.—FDA's Obligations Under the 1966 Public Information Act. Oct., p. 563.

Mandatory Regulations: Labeling Requirements and Regulatory Procedures. June, p. 348.

Markel, Michael F.—Foods for Special Dietary Uses—An Historical Outline of Regulatory Aspects. Feb., p. 110.

McFarlane, A. N.—In the Public Interest. Dec., p. 638.

Meats
Latin-American Food Code—Chapter VI. Aug., p. 421.

Mintener, Bradshaw.—Wanted—Lawyer-Statesman (The Charles Wesley Dunn Memorial Lecture). Apr., p. 242.

Model Food and Drug Law
Proposed amendments. May, p. 304.

Multiple Drug Litigation
The defendant's viewpoint. Mar., p. 145.
The plaintiff's viewpoint. Mar., p. 136.

Multiple Drug Litigation—The Defendant's Viewpoint. Mar., p. 145.

Multiple Drug Litigation—The Plaintiff's Viewpoint. Mar., p. 136.

Myers, Maven J.—Administrative Inspection of Health Facilities as Unreasonable Searches. Aug., p. 456.

N

New Developments in Food and Drug Legislation in Hawaii. Sept., p. 478.

O

Observations on Recent Developments in the Food, Drug and Cosmetic Law Field. Mar., p. 151.

Oser, Bernard L.—Food Additives in Japan. Nov., p. 611.

P

Package Insert: Significance, Style, Synthesis (The). Oct., p. 547.

Package Insert Requirement
The Package Insert: Significance, Style, Synthesis. Oct., p. 547.

Packaging Responsibilities of the FTC. Mar., p. 165.

Pendergast, William R.—A Quick Look at a Bad Decision. Aug., p. 416.

Pharmacy and the Future. Nov., p. 602.

Pharmacy
Pharmacy and the Future. Nov., p. 602.

Philosophy Behind the Fair Packaging and Labeling Act of 1966 (The). June, p. 322.

Post Office Department
Position on advertising of health literature. Jan., p. 4.

Prescription Drugs
FDA Goals in Labeling and Advertising Regulations. May, p. 300.
Safe and Effective Prescription-Drug Advertising. Jan., p. 57.
What FDA Expects in Prescription Drug Advertising. Jan., p. 46.

President's Message on Protection of the Consumer (The). Feb., p. 132.

Pricing
Food and Drug Advertising and Pricing Problems Under the Combines Investigation Act. Apr., p. 222.

Product Liability
Products liability today. Sept., p. 486.
Trend toward strict liability in tort. Feb., p. 125.

Product Liability—1966. Feb., p. 125.

Products Liability Today: Whither Thou Goest, I Will Go (A Modern Tale of Biblical Ruth and Naomi). Sept., p. 486.

Proposed Amendments to the Model Food and Drug Law. May, p. 304.

Proprietary Drugs
Forward With a Backward Look. July, p. 395.

Public Information Act of 1966
FDA's obligations. Oct., p. 563.

Purchasing and Subcontracting. Nov., p. 620.

Q

Quality Control
Assuring drug integrity. Feb., p. 85.

Question and Answer Panel of the FDA—FDLI Tenth Annual Educational Conference. Apr., p. 238; May, p. 264.

Quick Look at a Bad Decision (A). Aug., p. 416.

R

Rankin, Winton B.
FDA—Management Cooperation. Nov., p. 589.
FDA's Organization: The Reasons for Change. Dec., p. 660.

Reflections on Food Standards. Feb., p. 100.

Regulation
An Ombudsman for Industry. Sept., p. 472.
Factory Inspection. July, p. 407.
Factory Inspection Authority—The Statutory Viewpoint. Dec., p. 667.
Rule-making as Viewed by the Commissioner, the Congress, and the Court. Nov., p. 613.

Regulations
Status of Major Proposals and Regulations. Dec., p. 642.
The Color Additive Amendments of 1960 Revisited. Oct., p. 553.

Regulatory Programs
Food and Drug Regulatory Programs in England, Wales and Scotland. Nov., p. 576.

Reilly, John R.—The Role of the Federal Trade Commission. June, p. 338.

Reorganization
FDA's Organization: The Reasons for Change. Dec., p. 660.

Report from FDA. Feb., p. 68.

Reports to the Reader. Jan., p. 3; Feb., p. 67; Mar., p. 135; Apr., p. 199; May, p. 263; June, p. 311; July, p. 375; Aug., p. 415; Sept., p. 471; Oct., p. 527; Nov., p. 575; Dec., p. 631.

Rheingold, Paul D.—Multiple Drug Litigation—The Plaintiff's Viewpoint. Mar., p. 136.

Roe, Robert S.—Antibiotic Residues in Food. Jan., p. 41.

Rogers, Paul G.—The Philosophy Behind the Fair Packaging and Labeling Act of 1966. June, p. 322.

Role of the Department of Commerce (The). June, p. 327.

Role of the Department of Health, Education and Welfare (The). June, p. 334.

Role of the Federal Trade Commission (The). June, p. 338.

Rowe, Frederick M.—The Fair Packaging and Labeling Act of 1966: An Introductory Appraisal. June, p. 314.

Ruark, Robert G.—Salmonella in Food: Control in Manufacture and Distribution Jan., p. 25.

Rule-Making as Viewed by the Commissioner, the Congress, and the Court. Nov., p. 613.

S

Safe and Effective Prescription-Drug Advertising. Jan., p. 57.

Salmonella
Salmonella—History and Occurrence in Foods. Jan., p. 20.
Salmonella in Food: Control in Manufacture and Distribution. Jan., p. 25.
Status and Review of the Salmonella Program. Dec., p. 655.

Salmonella in Food: Control in Manufacture and Distribution. Jan., p. 25.

Salmonella—History and Occurrence in Foods. Jan., p. 20.

Seizure
Factory Inspection. July, p. 407.

Similarities of and Differences Between the Food Laws of France and the United States. July, p. 386.

Sinotte, L. Paul.—Assuring Drug Integrity—New Challenges, New Horizons. Feb., p. 85.

Some Observations on the Current Status of Drug Law. Apr., p. 200.

Spirituous Beverages
Latin-American Food Code—Chapter XV. Oct., p. 528.

State Regulations
Industry Views on FDA's Labeling Proposal and State Regulations. Apr., p. 254.
Status of Major Proposals and Regulations. Dec., p. 642.
Status and Review of the Salmonella Program. Dec., p. 655.
van der Steur, J. P. K.—Similarities of and Differences Between the Food Laws of France and the United States. July, p. 386.
Stimulating Products
Latin-American Food Code—Chap. XVI. May, p. 285.
Subcontracting
Purchasing and Subcontracting. Nov., p. 620.
Sweeny, Charles A.
Packaging Responsibilities of the FTC. Mar., p. 165.
Key Issues Posed for FTC Staff by the Act—Coverage of the Act. June, p. 344.

T

Trends in Drug Legislation Under the Food and Drugs Act in Canada. Mar., p. 189.
Truth-In-Packaging Revisited. June, p. 317.
Turner, Donald F.—Antitrust Aspects of Industry Cooperation and Product Standardization. June, p. 361.

U

United Kingdom
Food and Drug Regulatory Programs in England, Wales and Scotland. Nov., p. 576.
Use of Human Subjects in Safety Evaluation of Food Chemicals: Proceedings of a Conference (Review of). Oct., p. 569.
Unreasonable Searches
Administrative Inspection of Health Facilities as Unreasonable Searches. Aug., p. 456.

V

Veterinary Medical and Nonmedical Uses of Antibiotics. Jan., p. 33.
Voluntary Compliance. Dec., p. 672.
Voluntary Compliance
Voluntary Compliance. Dec., p. 672.
FDA's Voluntary Compliance Program. Dec., p. 682.
Is Government by Exhortation Desirable? Dec., p. 647.

W

Wanted — Lawyer-Statesmen (The Charles Wesley Dunn Memorial Lecture). Apr., p. 242.
Weigel, W. F.—Purchasing and Subcontracting. Nov., p. 620.
Welcoming Remarks (1966 FDA-FDLI Conference). Jan., p. 18.
What FDA Expects in Prescription Drug Advertising. Jan., p. 46.
What the Public Expects of FDA—A Third Party Arbiter. Apr., p. 234.
Woodworth, James R.—Food and Drug Regulatory Programs in England, Wales and Scotland. Nov., p. 576.

Y

Year in Review (The). Feb., p. 92.